Functional analysis/name | P value | Number of molecules |
---|---|---|
Diseases and disorders | ||
 Cancer | 2.47E − 09–4.63E − 03 | 770 |
 Renal and urological disease | 3.66E − 08–3.83E − 03 | 99 |
 Inflammatory response | 6.96E − 08–4.28E − 03 | 263 |
 Immunological disease | 3.91E − 07–3.15E − 03 | 219 |
 Hematological disease | 4.54E − 07–4.41E − 03 | 141 |
Molecular and cellular functions | ||
 Cellular movement | 5.28E − 11–4.43E − 03 | 295 |
 Cell death and survival | 2.11E − 07–4.72E − 03 | 437 |
 Cell morphology | 8.16E − 07–4.94E − 03 | 105 |
 Cellular growth and proliferation | 1.51E − 06–4.17E − 03 | 423 |
 Cellular development | 2.62E − 06–4.92E − 03 | 372 |
Physiological system development and function | ||
 Cardiovascular system development and function | 1.54E − 08–4.83E − 03 | 208 |
 Organismal development | 3.30E − 08–4.83E − 03 | 260 |
 Hematological system development and function | 6.96E − 08–4.92E − 03 | 258 |
 Immune cell trafficking | 6.96E − 08–4.43E − 03 | 268 |
 Embryonic development | 8.16E − 07–3.34E − 03 | 147 |
Canonical pathway analysis/name | P value | Ratio |
 Antigen presentation pathway | 1.89E − 05 | 12/42 (0.286) |
 Cytotoxic T lymphocyte-mediated apoptosis of target cells | 1.35E − 04 | 12/88 (0.136) |
 Dendritic cell maturation | 1.48E − 04 | 28/211 (0.133) |
 Molecular mechanisms of cancer | 2.27E − 04 | 47/387 (0.121) |
 Crosstalk between dendritic cells and natural killer cells | 2.7E − 04 | 18/106 (0.170) |